119
Views
3
CrossRef citations to date
0
Altmetric
Meta-analysis

Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials

, , , , , & show all
Pages 95-102 | Received 14 Jan 2021, Accepted 06 May 2021, Published online: 15 Jun 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Chien-Ming Chao, Teng-Song Weng, Yu-Hung Chen, Chih-Cheng Lai & Wei-Ting Lin. (2022) Anti-MRSA quinolones for acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Anti-infective Therapy 20:5, pages 733-739.
Read now

Articles from other publishers (2)

Konstantinos Leventogiannis, Maria Mouktaroudi & Evangelos J. Giamarellos-Bourboulis. (2023) Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections. Current Opinion in Infectious Diseases 36:2, pages 89-94.
Crossref
Ching-Yi Chen, Wang-Chun Chen, Chih-Cheng Lai, Tzu-Ping Shih & Hung-Jen Tang. (2021) Anti-MRSA Cephalosporin versus Vancomycin-Based Treatment for Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Antibiotics 10:8, pages 1020.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.